Gapping up
In reaction to earnings/guidance:
- UPST +20.9%, LPRO +16.1%, FUBO +13.5%, NVEE +8.9%, MRVI +7.9%, TDUP +7.3%, PUBM +7.1%, SKIN +6.7%, JAMF +5%, TASK +4.8%, DOCS +4.6%, RPRX +4.3%, WEN +3.9%, MCFE +3.7%, COIN +2.7%, SHCR +2.7%, TBLA +2.6%, THRY +2%, FLYW +1.9%, DAR +1.7%, OLO +1.6% (also to team up with GRUB to integrate digital orders), U +1.2% (also to acquire Parsec for $320 mln in cash)
Other news:
- FULC +11.3% (stock offering)
- BCRX +9.7% (withdraws its proposed public offering)
- CRNX +8% (stock offering by selling shareholders; also files for mixed securities shelf offering)
- AKUS +7.8% (announces European Commission designation of AK-OTOF for the treatment of otoferlin gene-mediated hearing loss as an Orphan Drug)
- EYES +4.5% (announces a new NIH grant supplement for its Orion study)
- AGFY +4.4% (announces second TTK partnership with True House Cannabis)
- NLOK +3.5% (to acquire Avast)
- CHPT +1.7% (Humacyte announces that laboratory and preclinical data demonstrating the potential to engineer a biovascular pancreas as a method to transplant pancreatic islet cells for the long-term treatment of type 1 diabetes have been published in the Journal of Tissue Engineering)
- RIOT +1.5% (provides July production and operations updates)
- MESA +1.4% (reports July block hours increased 92.1% yr/yr)
Analyst comments:
- DHT +3.1% (upgraded to Buy from Hold at Stifel; upgraded to Buy from Neutral at H.C. Wainwright)
- BBWI +1.2% (upgraded to Outperform from Neutral at Robert W. Baird)